Dasher Neuroscience Completes Patient Recruitment for MSA Clinical Trial
Dasher Neuroscience has finished recruiting patients for its global Phase 2 clinical trial investigating its AI-based drug candidate YA-101 for the treatment of Multiple System Atrophy (MSA).
Dasher Neuroscience Holdings Inc. announced the completion of patient recruitment for a global Phase 2 clinical trial evaluating its AI-derived drug candidate, YA-101. The trial focuses on the treatment of Multiple System Atrophy (MSA), a progressive neurological disorder.
The study aims to assess the efficacy and safety of YA-101 in slowing or halting the progression of MSA. This condition currently has no cure, and YA-101 represents a potential new therapeutic avenue. Dasher Neuroscience specializes in the discovery and development of treatments for central nervous system (CNS) diseases.
Dasher Neuroscience utilizes artificial intelligence in its drug development process to identify and advance therapies for CNS conditions. The completion of recruitment for this Phase 2 trial is a significant step, and the company anticipates the study results will inform its ongoing development strategy for YA-101.